Detalhe da pesquisa
1.
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.
N Engl J Med
; 386(3): 220-229, 2022 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045228
2.
Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.
Clin Infect Dis
; 78(4): 833-841, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37823484
3.
Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool.
J Infect Dis
; 228(10): 1452-1455, 2023 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37540090
4.
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.
Clin Infect Dis
; 77(11): 1504-1510, 2023 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37539715
5.
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.
Gastroenterology
; 160(1): 115-127.e30, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32763240
6.
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
Clin Infect Dis
; 72(12): 2132-2140, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32255488
7.
SER-109 for Recurrent Clostridioides difficile Infection. Reply.
N Engl J Med
; 386(20): 1957-1958, 2022 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35584165
8.
Extended Follow-up of Microbiome Therapeutic SER-109 for Recurrent Clostridioides difficile Infection-Reply.
JAMA
; 329(12): 1033-1034, 2023 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36976280
9.
Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial.
JAMA
; 328(20): 2062-2064, 2022 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36260754
10.
A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection.
J Infect Dis
; 214(2): 173-81, 2016 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26908752
11.
Underascertainment of acute hepatitis C virus infections in the U.S. surveillance system: a case series and chart review.
Ann Intern Med
; 163(4): 254-61, 2015 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-26121304
12.
Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study.
J Infect Dis
; 212(9): 1407-19, 2015 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25883387
13.
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection.
Hepatology
; 59(1): 109-20, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23908124
14.
A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users.
Hepatology
; 57(3): 944-52, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23111904
15.
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.
JAMA Netw Open
; 6(2): e2255758, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36780159
16.
Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool.
Open Forum Infect Dis
; 9(9): ofac448, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36158136
17.
A "one-two punch" leading to hepatitis C seroconversion.
Clin Infect Dis
; 52(3): 361-3, 2011 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21189425
18.
The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Current Understanding and Gap Analysis.
Open Forum Infect Dis
; 7(5): ofaa114, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32405509
19.
Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria.
Clin Infect Dis
; 49(7): 1051-60, 2009 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19725787
20.
Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection.
Hepatology
; 48(5): 1700-12, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-18972443